Table 2 Pre-treatment evaluation among HCV treated at the Stockholm NSP (n = 162)

Genotype

n = 162 (%)

 1a

62 (38.3)

 1b

5 (3.1)

 2

25 (15.4)

 3a

70 (43.2)

Fibrosis score

n = 158

 Mean (SD) kPa

7.5 (4.0)

 Median (range) kPa

6.3 (3.4–33.8)

Fibrosis stages (kPa)

n = 158 (%)

 F0-F1 (< 7)

91 (57.6)

 F2 (7–9.4)

38 (24.1)

 F3 (9.5–12.4)

17 (10.8)

 F4 (≥ 12.5)

12 (7.6)

APRI score

n = 152

 Mean (SD)

0.5 (0.4)

 Median (range)

0.4 (0.09—2.3)

DAA treatment

n = 162 (%)

 Glecaprevir + Pibrentasvir

64 (39.5)

 Sofosbuvir + Ledispavir

61 (37.7)

 Sofosbuvir + Velpatasvir

36 (22.2)

 Elbasvir + Grazoprevir

1 (0.6)